This study is to evaluate the efficacy of post-exposure prevention and safety of HH-120 nasal spray in participants who are caregivers of hospitalized patients infected with SARS-CoV-2. HH-120 nasal spray are administrated 8-10 times to the participants per day until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
14
HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
Beijing Ditan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
The proportion of subjects infected with SARS-CoV-2
Time frame: As of the discharge of the SARS-CoV-2 infected patients, an average 1 week
The incidence and severity of adverse events and the serious adverse events
Time frame: As of the 7th day after the last study drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.